|
How and where to order Ribavirin (Copegus, Rebetol) 100 mg, 200 mg capsules and tablets online on the Autoimmune Information Network, Inc. website:
Shop: | PHARMA SHOP - 10% discount coupon hf-5478
|
Sellers: | RIBAVIRIN STORES
|
Prices: | from $3.76 per pill
|
Forms: | Ribavirin 100 mg, 200 mg tablets and capsules
|
Quantity: | 10-140 pills
|
Type: | Ribavirin brand, Copegus generic, Rebetol generic
|
Payment: | Visa, Mastercard, AmEx, Bitcoin
|
Delivery: | Regular and express mail service
|
Shipping: | Worldwide, including USA, UK, Europe, Canada, Australia |
Indications and usage:
Ribavirin (Copegus, Rebetol) is a nucleoside analogue indicated in combination with interferon alfa-2b (pegylated and nonpegylated) for the treatment of Chronic Hepatitis C (CHC) in patients 3 years of age or older with compensated liver disease.
Patients with the following characteristics are less likely to benefit from re-treatment after failing a course of therapy: previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, and genotype 1 infection.
Dosage and administration:
Ribavirin is administered according to body weight.
Dose reduction or discontinuation is recommended in patients experiencing certain adverse reactions or renal dysfunction.
Dosage forms and strengt:
Copegus (Ribavirin) tablets 100 mg, 200 mg.
Rebetol (Ribavirin) capsules 200 mg.
Rebetol (Ribavirin) oral solution 40 mg per mL.
Overdosage:
There is limited experience with overdosage. Acute ingestion of up to 20 g of ribavirin capsules, Intron A ingestion of up to 120 million units, and subcutaneous doses of INTRON A up to 10 times the recommended doses have been reported. Primary effects that have been observed are increased incidence and severity of the adverse reactions related to the therapeutic use of Intron A and Ribavirin (Copegus, Rebetol). However, hepatic enzyme abnormalities, renal failure, hemorrhage, and myocardial infarction have been reported with administration of single subcutaneous doses of Intron A that exceed dosing recommendations.
There is no specific antidote for Intron A or ribavirin overdose, and hemodialysis and peritoneal dialysis are not effective for treatment of overdose of these agents.
Contraindications:
Pregnancy and men whose female partners are pregnant
Known hypersensitivity reactions such as Stevens-Johnson syndrome, toxic, epidermal necrolysis, and erythema multiforme to ribavirin or any component of the product
Autoimmune hepatitis
Hemoglobinopathies
Creatinine clearance less than 50 mL/min
Coadministration of ribavirin with didanosine
Warnings and precautions:
Embryo-fetal toxicity: may cause fetal harm. Patients should have a negative pregnancy test prior to therapy and use effective contraception and undergo periodic pregnancy tests.
Patients exhibiting the following conditions should be closely monitored and may require dose reduction or discontinuation of therapy:
Hemolytic anemia may occur with a significant initial drop in hemoglobin.
Pancreatitis.
Pulmonary infiltrates or pulmonary function impairment.
New or worsening ophthalmologic disorders.
Severe decreases in neutrophil and platelet counts, and hematologic, endocrine (e.g., TSH), and hepatic abnormalities.
Dental/periodontal disorders reported with combination therapy.
Concomitant administration of azathioprine.
Weight loss and growth inhibition reported during combination
therapy in pediatric patients. Long-term growth inhibition (height) reported in some patients.
Monotherapy with ribavirin is not permitted.
Adverse reactions, side effects:
Hemolytic anemia occurred in more than 10% of adult patients receiving Rebetol/PegIntron or Intron A combination therapy.
Most common adverse reactions (40% or greater) in adult patients receiving Copegus or Rebetol/PegIntron or Intron A combination therapy are injection site reaction, fatigue/asthenia, headache, rigors, fevers, nausea, myalgia and anxiety/emotional lability/irritability. Most common adverse reactions (greater than 25%) in pediatric patients receiving Rebetol/PegIntron therapy are: pyrexia, headache, neutropenia, fatigue, anorexia, injection site erythema, and vomiting.
To report suspected side effects of Copegus or Rebetol (Ribavirin) capsules and tablets contact Roche and Merck pharmaceutical companies, or your local FDA.
Drug interactions:
Nucleoside analogues: closely monitor for toxicities. Discontinue nucleoside reverse transcriptase inhibitors or reduce dose or discontinue interferon, ribavirin or both with worsening toxicities.
Related medications:
Molnupiravir in the USA, UK, Australia
Valacyclovir (Valtrex)
Use in specific populations:
Pediatrics: safety and efficacy in patients less than 3 years old have not been established.
Organ transplant recipients: safety and efficacy not studied.
Co-infected patients: safety and efficacy with HIV or HBV co-infection have not been established.
Patient counseling information:
Anemia
The most common adverse experience occurring with Ribavirin (Copegus, Rebetol) capsules and tablets is anemia, which may be severe. Advise patients that laboratory evaluations are required prior to starting therapy and periodically thereafter. Advise patients to be well hydrated, especially during the initial stages of treatment.
Embryo-fetal toxicity
Inform females of reproductive potential and pregnant women that ribavirin pills and oral solution may cause birth defects, miscarriage, and stillbirth. Advise females of reproductive potential that they must have a pregnancy test prior to initiating treatment and periodically during therapy.
Advise females of reproductive potential and male patients with female partners of reproductive potential to use effective contraception during treatment with Copegus or Rebetol and for 6 months post therapy. Advise patients to notify the physician immediately in the event of a pregnancy.
Missed dose
Inform patients that in the event a dose is missed, the missed dose should be taken as soon as possible during the same day. Patients should not double the next dose. Advise patients to contact their healthcare provider if they have questions.
Dental and periodontal disorders
Advise patients to brush their teeth thoroughly twice daily and have regular dental examinations. If vomiting occurs, advise patients to rinse out their mouth thoroughly afterwards.
Where to buy ribavirin online:
To purchase Rebetol, Copegus (Ribavirin) 100 mg, 200 mg capsules and tablets from reliable online pharmacies and drugstores at low prices please use resources described above on this webpage.
Here is a list of popular medications containing ribavirin as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:
Trade name of the drug |
Pharmaceutical forms and doses |
Companies |
Copegus |
Tablets, Film-Coated; Oral; Ribavirin 200 mgTablets, Film-Coated; Oral; Ribavirin 400 mg |
RocheChugai PharmaceuticalDelphi PharmaceuticalsDKSHEmra-Med ArzneimittelG.A. Stamatis & Co.GenentechHaemato PharmOrifarmPatheon |
Rebetol |
Capsules; Oral; Ribavirin 200 mgSolution; Oral; Ribavirin 40 mg / ml |
Schering-PloughAescaAgencia Lei Va HongBayer Schering PharmaEssexFulford PharmaceuticalsMerckPfizerTrading PharmaZuellig Pharma |
Ribasphere |
Capsules; Oral; Ribavirin 200 mgTablets, Film-Coated; Oral; Ribavirin 200 mgTablets, Film-Coated; Oral; Ribavirin 400 mgTablets, Film-Coated; Oral; Ribavirin 600 mg |
Three Rivers PharmaceuticalsBiomeks IlacDSM PharmaceuticalsKadmon |
Ribavin |
Capsules; Oral; Ribavirin 100 mgCapsules; Oral; Ribavirin 200 mgSyrup; Oral; Ribavirin 50 mg / 5 ml |
Lupin PharmaceuticalsPinnacle CVS |
Virazole |
Injectable; Infusion; Ribavirin 100 mg / mlPowder for Solution; Inhalation; Ribavirin 6 g |
Valeant PharmaceuticalsAntigen PharmaceuticalsEgyptian Pharmaceutical CompanyFirma Chun CheongICN PharmaceuticalsIDS GroupInex-IntherexportInvidaJDH PharmaceuticalLegacy PharmaceuticalsMedaOrphan PharmaceuticalSanicoSanofi-AventisUCI-Farma Industria FarmaceuticaViraTekZuellig Pharma |
Home | Diagnosis | List of Diseases | Support Group Info | Join Our Mailing List
Copyright © 2005 - 2022 Autoimmune Information Network, Inc. All Rights Reserved.
|
|
|